Dark Forest Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Dark Forest Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,706	Closed	-$94.6K	–	1330
2024 Q3	$94.6K	Buy	+25,706	New	+$93.4K	0.01%	921
2022 Q3	–	Sell	-3	Closed	–	–	1483
2022 Q2	$0	Buy	+3	New	+$79	﹤0.01%	1442
2022 Q1	–	Sell	-463	Closed	-$39K	–	1826
2021 Q4	$39K	Sell	463 -721	-61%	-$55.8K	0.01%	497
2021 Q3	$79K	Buy	+1,184	New	+$68.3K	0.03%	454

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dark Forest Capital Management's ZNTL Position: Q4 2024 in Review

Dark Forest Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 25,706 shares — an estimated $94.6K sold.

Dark Forest Capital Management first reported a position in ZNTL in Q3 2021 and held it in 4 quarters. The position peaked at $94.6K in Q3 2024. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

Dark Forest Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Dark Forest Capital Management sold 25,706 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $94.6K.
Dark Forest Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 4 quarters.
Dark Forest Capital Management's Zentalis Pharmaceuticals position peaked at $94.6K in Q3 2024.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Dark Forest Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.